drugset / Trial / NCT06424899
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially operable stage III NSCLC.
Timeline
- Start
- 2024-05-19
- Primary completion
- 2027-05-19
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Nedaplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | Vinblastine | Small molecule | — | — |
| Background | Vinorelbine | Small molecule | — | — |
| Background | paclitaxel liposomes | Unknown | — | — |